Get the Stockscreener App
2.25
0.45%
0.010
Aytu Biopharma Inc stock is traded at $2.25, with a volume of 10,412.
It is up +0.45% in the last 24 hours and up +5.63% over the past month.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
See More
Previous Close:
$2.24
Open:
$2.25
24h Volume:
10,412
Relative Volume:
0.34
Market Cap:
$24.15M
Revenue:
$56.60M
Net Income/Loss:
$-34.12M
P/E Ratio:
-0.4908
EPS:
-4.5844
Net Cash Flow:
$-1.36M
1W Performance:
-5.06%
1M Performance:
+5.63%
6M Performance:
-12.45%
1Y Performance:
-2.60%
1-Day Range:
$2.25
$2.2995
1-Week Range:
$2.2353
$2.38
52-Week Range:
$1.6501
$3.065
Aytu Biopharma Inc Stock (AYTU) Company Profile
Name
Aytu Biopharma Inc
Sector
Phone
(720) 437-6580
Address
7900 E. UNION AVENUE, DENVER
Compare AYTU vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AYTU
Aytu Biopharma Inc
|
2.25 | 24.47M | 56.60M | -34.12M | -1.36M | -4.5844 |
TAK
Takeda Pharmaceutical Co Adr
|
18.03 | 57.90B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
10.11 | 43.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.44 | 42.89B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.34 | 31.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
515.46 | 22.35B | 3.17B | 1.29B | 1.01B | 27.09 |
Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Initiated | Lake Street | Buy |
| Jun-30-25 | Initiated | Ascendiant Capital Markets | Buy |
| Mar-30-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-29-20 | Initiated | H.C. Wainwright | Buy |
Aytu Biopharma Inc Stock (AYTU) Latest News
Aytu (AYTU) Q2 2026 Earnings: EPS Misses Its Estimate; Closing Move: The Market Reaction Is Muted in the Current UpdatePerformance Review - vinanet.vn
Aytu BioPharma (AYTU) investor and foundation each report 4.99% beneficial stake - Stock Titan
ACTU Stock Price and Chart — NASDAQ:ACTU - TradingView
Aytu BioPharma (AYTU) Slips 1.7% to $2.36 as Biotech Volatility PersistsRisk Parity Rebalance - vinanet.vn
Aytu Biopharma Inc (AYTU) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
AYTU Q2 2026 Earnings: Narrow EPS Miss Slightly Wider Than Expected, Shares Rise 1.69%Earnings Expansion Phase - vinanet.vn
Aytu Biopharma Inc (AYTU) Stock News Today - TradingKey
Aytu BioPharma, Inc. (0A8M.L) valuation measures and financial statistics - Yahoo Finance Australia
CNSY Stock Price and Chart — NASDAQ:CNSY - TradingView
Aytu BioPharma (AYTU) Climbs 3.72% to $2.23 — Approaching Key ResistanceBreadth Thrust - vinanet.vn
Aytu BioScience Inc (0A8M) Q2 2026 Earnings ReportResults, Call & Slides - TipRanks
Aytu Biopharma Inc (AYTU) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Aytu Biopharma Inc (AYTU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aytu BioPharma Market Sentiment - Benzinga España
Aytu Biopharma Inc (AYTU) Cash Flow - TradingKey
Aytu Biopharma Inc (AYTU) Balance Sheet - TradingKey
AYTU|Aytu Biopharma Inc|Price:2.107|Chg%:+0.046 - TradingKey
AYTU|Aytu Biopharma Inc|Price:2.160| - TradingKey
Aytu Biopharma Inc (AYTU) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aytu Biopharma Inc (AYTU) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aytu Biopharma Inc (AYTU) Income Statement - TradingKey
AYTU Q2 2026 Earnings: EPS Misses Estimates by Nearly 2%, Stock Holds SteadyProfit Announcement - vinanet.vn
Aytu BioPharma, Inc. Revenue Breakdown – NASDAQ:AYTU - TradingView
AYTU Q2 2026 Earnings: EPS Slightly Misses Estimates with Minimal SurprisePerformance Review - vinanet.vn
AYTU Q2 2026 Earnings: EPS Misses Estimates Amid Challenging QuarterCore Business Growth - vinanet.vn
Aytu BioPharma (AYTU) Edges Higher as Stock Tests Key ResistanceOvernight Profile - vinanet.vn
AYTU Q2 2026 Earnings: EPS Misses Estimates Amid No Revenue; Stock Edges HigherCapex Guidance - vinanet.vn
AYTU Q2 2026 Earnings: EPS Misses Consensus, Stock Falls SlightlyRevenue Guidance Update - vinanet.vn
AYTU Q2 2026 Earnings: EPS Misses Estimates, Stock DeclinesNet Income Trends - vinanet.vn
AYTU Q2 2026 Earnings: EPS Misses Estimates, Shares Edge HigherPost-Earnings Drift - Vinanet
AYTU Q2 2026 Earnings: EPS Misses Estimates Amid Narrow Loss; Stock Edges HigherPost-Earnings Drift - vinanet.vn
Aytu BioPharma (AYTU) Edges Higher, Testing Key Resistance LevelsGap Fill Strategy - dars.gov.et
AYTU Q2 2026 Earnings: EPS Miss Slightly Wider Than Expected; Stock Rises 2.74% Amid Strategic ReviewEarnings Beat Streak - dars.gov.et
AYTU Q2 2026 Earnings: EPS Misses Estimates Slightly, Stock Edges HigherNet Profit Margin - dars.gov.et
Aytu BioPharma Holds Steady Near $2.16 Amid Modest Gains – Key Levels in FocusFactor Valuation - DonanımHaber
Aytu BioPharma | SCHEDULE 13G/A: Others - Moomoo
Aytu BioPharma, Inc. (AYTU) reports Q3 loss, tops revenue estimates - MSN
Aytu BioPharma, Inc. Actuals & Estimates (NASDAQ:AYTU) - TradingView
AYTU Forecast — Price Target — Prediction for 2027 - TradingView
Aytu BioPharma, Inc. Actuals & Estimates (LSE:0A8M) - TradingView
0A8M Forecast — Price Target — Prediction for 2027 - TradingView
Aytu Biopharmato Continue Selling Existing - Moomoo
Aytu BioPharma Ends Metadate CD License With Lannett; Sell-Through Allowed After Mutual Termination - TradingView
Aytu BioPharma (AYTU) ends Metadate CD license agreement with Lannett - Stock Titan
Price to sales forward of Aytu BioPharma, Inc. – NASDAQ:AYTU - TradingView
Enterprise value to EBIT forward of Aytu BioPharma, Inc. – NASDAQ:AYTU - TradingView
Enterprise value to revenue forward of Aytu BioPharma, Inc. – NASDAQ:AYTU - TradingView
AYTU Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Aytu Biopharma Inc (AYTU) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Aytu BioPharma Surges 9.7%: Key Levels and Potential Catalysts for AYTU StockDark Pool Sentiment - dars.gov.et
Aytu Biopharma Inc (AYTU) Valuation: PE, PB & Fair Value Analysis - TradingKey
Aytu Biopharma Inc Stock (AYTU) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.05%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):